Levels of anti-Müllerian hormone (AMH) may not correlate with ovarian reserve in patients with breast cancer, suggests a study presented at ESHRE 2018, thus raising questions on the utility of AMH testing before hormonal stimulation in fertility preservation for women with breast cancer.
Chemotherapy may be less damaging to fertility of female lymphoma patients who are of a younger age than those who are older, even in the case of an alkylating regimen, suggests a study presented at ESHRE 2018.
The increased risk of prostate cancer, particularly early-onset prostate cancer, among subfertile men who undergo intracytoplasmic sperm injection (ICSI) does not appear to be due to the procedure, according to a nationwide, registry-based study from Sweden.
Tubal flushing with oil-based contrast medium at hysterosalpingography (HSG) leads to a higher ongoing pregnancy rate beyond the previously reported results at 6 months, with significantly shorter time to ongoing pregnancy than flushing with water-based contrast, according to a study presented at ESHRE 2018.
Dual triggering with a gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) may increase the number of oocytes among women undergoing in vitro fertilization (IVF), according to a study presented at ESHRE 2018.
Endometrial scratching prior to in vitro fertilization (IVF) failed to improve live birth rates in the PIP* study, challenging a practice currently embraced by gynaecologists to boost the chances of embryo implantation in subfertile women.
Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.